Abstract
The progress in genome-scale approaches to human diseases will soon require to understand the function of a large number of genes as potentially interesting therapeutic targets. The determination of their biological role needs to be accelerated in order to select valid therapeutic targets and streamline the drug discovery process. The sequencing of the human genome, as well as a number of model organisms, provides a strong framework to achieve this goal. Several methods among which gene expression profiling and protein interaction mapping are being used on a large-scale basis and constitute useful entry points to identify pathways involved in disease mechanisms. The resulting information is however limited. Other methods rely on the genetic manipulation of well-characterized and simple model organisms (SMOs) to reconstruct human disease-associated pathways and pinpoint biologically-valid therapeutic targets on the basis of function-based datasets generated in vivo. SMOs are strongly complementary to well-established complex mammalian models, and multiple ways exist to integrate SMOs into the early stage of the drug discovery process. In this review, we attempt to highlight some of the general criteria and essential methodological components associated with the use of SMO technologies for rapid functional genomics. Examples are provided to illustrate the utility of C. elegans and Drososphila for the validation of targets for central nervous system drugs.
Keywords: Therapeutic Targets, Simple model organisms SMOs, ESTs, CDNAs, Protein, EST expression Profiles, Biallelic Single uncleotide markers, DNA array, Proteomics, Target Validation
Current Genomics
Title: Defining Therapeutic Targets in Simple Model Organisms
Volume: 1 Issue: 2
Author(s): F. Thomas and C. Neri
Affiliation:
Keywords: Therapeutic Targets, Simple model organisms SMOs, ESTs, CDNAs, Protein, EST expression Profiles, Biallelic Single uncleotide markers, DNA array, Proteomics, Target Validation
Abstract: The progress in genome-scale approaches to human diseases will soon require to understand the function of a large number of genes as potentially interesting therapeutic targets. The determination of their biological role needs to be accelerated in order to select valid therapeutic targets and streamline the drug discovery process. The sequencing of the human genome, as well as a number of model organisms, provides a strong framework to achieve this goal. Several methods among which gene expression profiling and protein interaction mapping are being used on a large-scale basis and constitute useful entry points to identify pathways involved in disease mechanisms. The resulting information is however limited. Other methods rely on the genetic manipulation of well-characterized and simple model organisms (SMOs) to reconstruct human disease-associated pathways and pinpoint biologically-valid therapeutic targets on the basis of function-based datasets generated in vivo. SMOs are strongly complementary to well-established complex mammalian models, and multiple ways exist to integrate SMOs into the early stage of the drug discovery process. In this review, we attempt to highlight some of the general criteria and essential methodological components associated with the use of SMO technologies for rapid functional genomics. Examples are provided to illustrate the utility of C. elegans and Drososphila for the validation of targets for central nervous system drugs.
Export Options
About this article
Cite this article as:
Thomas F. and Neri C., Defining Therapeutic Targets in Simple Model Organisms, Current Genomics 2000; 1 (2) . https://dx.doi.org/10.2174/1389202003351544
DOI https://dx.doi.org/10.2174/1389202003351544 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design Editorial (Thematic Issue: The Activity of Products from Cnidaria: A Therapeutic Tool in Neurological Diseases - Part 1)
Central Nervous System Agents in Medicinal Chemistry Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Neuropsychiatric Properties of the ACE2/Ang-(1-7)/Mas Pathway: A Brief Review
Protein & Peptide Letters New Aspects of Monoamine Oxidase B Inhibitors: The Key Role of Halogens to Open the Golden Door
Current Medicinal Chemistry Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Hippocampal Neurogenesis, Neurotrophic Factors and Depression: Possible Therapeutic Targets?
CNS & Neurological Disorders - Drug Targets UCP2 and CFH Gene Variants with Genetic Susceptibility to Schizophrenia in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets 2D & 3D-QSAR Study on Novel Piperidine and Piperazine Derivatives as Acetylcholinesterase Enzyme Inhibitors
Current Computer-Aided Drug Design Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets Inflammatory Mediators in Smoke Inhalation Injury
Inflammation & Allergy - Drug Targets (Discontinued) The Structure and Main Functions of Aminopeptidase N
Current Medicinal Chemistry MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Gq protein-Coupled Receptors as Targets for Anesthetics
Current Pharmaceutical Design Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis
Current HIV Research Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Synthesis of 2,5-Disubstituted-1,3,4-oxadiazole Analogs as Novel Anticancer and Antimicrobial Agents
Letters in Drug Design & Discovery Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Transient Cerebral Ischemia Leads to TGF-β2 Expression in Golgi Apparatus Organelles
Current Neurovascular Research Immunotoxins in the Treatment of Hematologic Malignancies
Current Drug Targets